Solid Lipid Nanoparticles: A Promising Nanomaterial in Drug Delivery

Author(s): Kuldeep Rajpoot*

Journal Name: Current Pharmaceutical Design

Volume 25 , Issue 37 , 2019

Become EABM
Become Reviewer

Abstract:

The solid lipid nanoparticles (SLNs) usually consists of active drug molecules along with solid lipids, surfactants, and/or co-surfactants. They possess some potential features such as nano-size, surface with a free functional group to attach ligands, and as well they prove safe homing for both lipophilic as well as hydrophilic molecules. As far as synthesis is concerned, SLNs can be prepared by employing various techniques viz., homogenization techniques (e.g., high-pressure, high-speed, cold, or hot homogenization), spray drying technique, ultrasonication, solvent emulsification, double emulsion technique, etc. Apart from this, they are characterized by different methods for determining various parameters like particle-size, polydispersity-index, surface morphology, DSC, XRD, etc. SLNs show good stability as well as the ability for surface tailoring with the specific ligand, which makes them a suitable candidate in the therapy of numerous illnesses, especially in the targeting of the cancers. In spite of this, SLNs have witnessed their application via various routes e.g., oral, parenteral, topical, pulmonary, rectal routes, etc. Eventually, SLNs have also shown great potential for delivery of gene/DNA, vaccines, as well as in cosmeceuticals. Hence, SLNs have emerged as a promising nanomaterial for efficient delivery of various Active Pharmaceutical Ingredients (APIs).

Keywords: Solid lipid nanoparticles, nanomaterials, nanostructured lipid carriers, lipid drug conjugates, drug delivery, targeted delivery.

[1]
Carvalho IPS, Miranda MA, Silva LB, et al. In vitro anticancer activity and physicochemical properties of Solanum lycocarpum alkaloidic extract loaded in natural lipid-based nanoparticles. Colloid Interfac Sci 2019; 28: 5-14.
[http://dx.doi.org/10.1016/j.colcom.2018.11.001]
[2]
Myhrvold C, Polka JK, Silver PA. Synthetic lipid-containing scaffolds enhance production by colocalizing enzymes. ACS Synth Biol 2016; 5: 1396-403.
[http://dx.doi.org/10.1021/acssynbio.6b00141] [PMID: 27487319]
[3]
Mukherjee S, Ray S, Thakur RS. Solid lipid nanoparticles: a modern formulation approach in drug delivery system. Indian J Pharm Sci 2009; 71: 349-58.
[http://dx.doi.org/10.4103/0250-474X.57282] [PMID: 20502539]
[4]
Irby D, Du C, Li F. Lipid-drug conjugate for enhancing drug delivery. Mol Pharm 2017; 14: 1325-38.
[http://dx.doi.org/10.1021/acs.molpharmaceut.6b01027] [PMID: 28080053]
[5]
Rai R, Alwani S, Badea I. Polymeric nanoparticles in gene therapy: new avenues of design and optimization for delivery applications. Polymers (Basel) 2019; 11: 745.
[http://dx.doi.org/10.3390/polym11040745] [PMID: 31027272]
[6]
Paliwal S, Tilak A, Sharma J, et al. Flurbiprofen loaded ethosomes - transdermal delivery of anti-inflammatory effect in rat model. Lipids Health Dis 2019; 18: 133.
[http://dx.doi.org/10.1186/s12944-019-1064-x] [PMID: 31170970]
[7]
Xia Q, Ling L, Ismail M, et al. Paclitaxel encapsulated in artesunate-phospholipid liposomes for combinatorial delivery. J Drug Deliv Sci Technol 2019; 51: 372-82.
[http://dx.doi.org/10.1016/j.jddst.2019.03.010]
[8]
Souto EB, Doktorovova S, Campos JR, Martins-Lopes P, Silva AM. Surface-tailored anti-HER2/neu-solid lipid nanoparticles for site-specific targeting MCF-7 and BT-474 breast cancer cells. Eur J Pharm Sci 2019; 128: 27-35.
[http://dx.doi.org/10.1016/j.ejps.2018.11.022] [PMID: 30472221]
[9]
Shen M-Y, Liu T-I, Yu T-W, et al. Hierarchically targetable polysaccharide-coated solid lipid nanoparticles as an oral chemo/thermotherapy delivery system for local treatment of colon cancer. Biomaterials 2019; 197: 86-100.
[http://dx.doi.org/10.1016/j.biomaterials.2019.01.019] [PMID: 30641267]
[10]
Abdelaziz HM, Freag MS, Elzoghby AO. Chapter 5 - Solid Lipid Nanoparticle-Based Drug Delivery for Lung Cancer. In: Kesharwani P, Ed. Nanotechnology-Based Targeted Drug Delivery Systems for Lung Cancer: Academic Press 2019; p. 95-121.
[http://dx.doi.org/10.1016/B978-0-12-815720-6.00005-8]
[11]
Rajpoot K, Jain SK. Colorectal cancer-targeted delivery of oxaliplatin via folic acid-grafted solid lipid nanoparticles: preparation, optimization, and in vitro evaluation. Artif Cells Nanomed Biotechnol 2018; 46: 1236-47.
[http://dx.doi.org/10.1080/21691401.2017.1366338] [PMID: 28849671]
[12]
El-Say KM, Hosny KM. Optimization of carvedilol solid lipid nanoparticles: an approach to control the release and enhance the oral bioavailability on rabbits. PLoS One 2018; 13 e0203405
[13]
Wu X, Chen H, Wu C, et al. Inhibition of intrinsic coagulation improves safety and tumor-targeted drug delivery of cationic solid lipid nanoparticles. Biomaterials 2018; 156: 77-87.
[http://dx.doi.org/10.1016/j.biomaterials.2017.11.040] [PMID: 29190500]
[14]
Gohla SH, Dingler A. Scaling up feasibility of the production of solid lipid nanoparticles (SLN). Pharmazie 2001; 56: 61-3.
[PMID: 11210672]
[15]
Lee S-E, Lee CD, Ahn JB, et al. Hyaluronic acid-coated solid lipid nanoparticles to overcome drug-resistance in tumor cells. J Drug Deliv Sci Technol 2019; 50: 365-71.
[http://dx.doi.org/10.1016/j.jddst.2019.01.042]
[16]
Vieira ACC, Chaves LL, Pinheiro S, et al. Mucoadhesive chitosan-coated solid lipid nanoparticles for better management of tuberculosis. Int J Pharm 2018; 536: 478-85.
[http://dx.doi.org/10.1016/j.ijpharm.2017.11.071] [PMID: 29203137]
[17]
Muller RH, Mader K, Gohla S. Solid lipid nanoparticles (SLN) for controlled drug delivery - a review of the state of the art. Eur J Pharm Biopharm 2000; 50: 161-77.
[http://dx.doi.org/10.1016/S0939-6411(00)00087-4] [PMID: 10840199]
[18]
Chen H, Khemtong C, Yang X, Chang X, Gao J. Nanonization strategies for poorly water-soluble drugs. Drug Discov Today 2011; 16: 354-60.
[http://dx.doi.org/10.1016/j.drudis.2010.02.009] [PMID: 20206289]
[19]
Qiu S, Liang D, Guo F, et al. Solid lipid nanoparticles modified with amphipathic chitosan derivatives for improved stability in the gastrointestinal tract. J Drug Deliv Sci Technol 2018; 48: 288-99.
[http://dx.doi.org/10.1016/j.jddst.2018.10.007]
[20]
Talegaonkar S, Bhattacharyya A. Potential of lipid nanoparticles (SLNs and NLCs) in enhancing oral bioavailability of drugs with poor intestinal permeability. AAPS PharmSciTech 2019; 20: 121.
[http://dx.doi.org/10.1208/s12249-019-1337-8] [PMID: 30805893]
[21]
Özdemir S, Çelik B, Üner M. Chapter 15 - Properties and therapeutic potential of solid lipid nanoparticles and nanostructured lipid carriers as promising colloidal drug delivery systems. In: Holban A-M, Grumezescu AM, Eds. Materials for Biomedical Engineering: Elsevier; 2019. p. 451-99.
[22]
Ding Y, Nielsen KA, Nielsen BP, Bøje NW, Müller RH, Pyo SM. Lipid-drug-conjugate (LDC) solid lipid nanoparticles (SLN) for the delivery of nicotine to the oral cavity - Optimization of nicotine loading efficiency. Eur J Pharm Biopharm 2018; 128: 10-7.
[http://dx.doi.org/10.1016/j.ejpb.2018.03.004] [PMID: 29545120]
[23]
Kelidari HR, Babaei R, Nabili M, et al. Improved delivery of voriconazole to Aspergillus fumigatus through solid lipid nanoparticles as an effective carrier. Colloids Surf Physicochem Eng Aspects 2018; 558: 338-42.
[http://dx.doi.org/10.1016/j.colsurfa.2018.08.082]
[24]
Suresh Reddy J, Venkateswarlu V. Novel delivery systems for drug targeting to the brain. Drugs Future 2004; 29: 63-83.
[http://dx.doi.org/10.1358/dof.2004.029.01.872585]
[25]
Chen DB, Yang TZ, Lu WL, Zhang Q. In vitro and in vivo study of two types of long-circulating solid lipid nanoparticles containing paclitaxel. Chem Pharm Bull (Tokyo) 2001; 49: 1444-7.
[http://dx.doi.org/10.1248/cpb.49.1444] [PMID: 11724235]
[26]
Tabatt K, Sameti M, Olbrich C, Muller RH, Lehr CM. Effect of cationic lipid and matrix lipid composition on solid lipid nanoparticle-mediated gene transfer. Eur J Pharm Biopharm 2004; 57: 155-62.
[http://dx.doi.org/10.1016/j.ejpb.2003.10.015] [PMID: 15018970]
[27]
Joshi MD, Prabhu RH, Patravale VB. Fabrication of Nanostructured Lipid Carriers (NLC)-Based Gels from Microemulsion Template for Delivery Through Skin In: Weissig V, Elbayoumi T, (editors) Pharmaceutical Nanotechnology: Basic Protocols New York, NY: Springer 2019; p 279-92
[http://dx.doi.org/10.1007/978-1-4939-9516-5_19]
[28]
Khan S, Ganguli M, Aditya A, Khan S, Baboota S, Ali J. Improved in vivo performance and immunomodulatory effect of novel Omega-3 fatty acid based tacrolimus nanostructured lipid carrier. J Drug Deliv Sci Technol 2019; 52: 138-49.
[http://dx.doi.org/10.1016/j.jddst.2019.04.019]
[29]
Sharma M, Pandey C, Sharma N, Kamal MA, Sayeed U, Akhtar S. Cancer Nanotechnology-An Excursion on Drug Delivery Systems. Anticancer Agents Med Chem 2018; 18: 2078-92.
[30]
Taymouri S, Alem M, Varshosaz J, Rostami M, Akbari V, Firoozpour L. Biotin decorated sunitinib loaded nanostructured lipid carriers for tumor targeted chemotherapy of lung cancer. J Drug Deliv Sci Technol 2019; 50: 237-47.
[http://dx.doi.org/10.1016/j.jddst.2019.01.024]
[31]
Olbrich C, Gessner A, Kayser O, Muller RH. Lipid-drug-conjugate (LDC) nanoparticles as novel carrier system for the hydrophilic antitrypanosomal drug diminazenediaceturate. J Drug Target 2002; 10: 387-96.
[http://dx.doi.org/10.1080/1061186021000001832] [PMID: 12442809]
[32]
Patil H, Kulkarni V, Majumdar S, Repka MA. Continuous manufacturing of solid lipid nanoparticles by hot melt extrusion. Int J Pharm 2014; 471: 153-6.
[http://dx.doi.org/10.1016/j.ijpharm.2014.05.024] [PMID: 24853459]
[33]
Momoh MA, Ossai EC, Chidozie OE, et al. A new lipid-based oral delivery system of erythromycin for prolong sustain release activity. Mater Sci Eng C Mater Biol Appl 2019; 97: 245-53.
[http://dx.doi.org/10.1016/j.msec.2018.12.041] [PMID: 30678909]
[34]
Neupane YR, Srivastava M, Ahmad N, Kumar N, Bhatnagar A, Kohli K. Lipid based nanocarrier system for the potential oral delivery of decitabine: formulation design, characterization, ex vivo, and in vivo assessment. Int J Pharm 2014; 477: 601-12.
[http://dx.doi.org/10.1016/j.ijpharm.2014.11.001] [PMID: 25445972]
[35]
Gad HA, Abd El-Rahman FAA, Hamdy GM. Chamomile oil loaded solid lipid nanoparticles: a naturally formulated remedy to enhance the wound healing. J Drug Deliv Sci Technol 2019; 50: 329-38.
[http://dx.doi.org/10.1016/j.jddst.2019.01.008]
[36]
Garg NK, Sharma G, Singh B, et al. Quality by Design (QbD)-enabled development of aceclofenac loaded-nano structured lipid carriers (NLCs): an improved dermatokinetic profile for inflammatory disorder(s). Int J Pharm 2017; 517: 413-31.
[http://dx.doi.org/10.1016/j.ijpharm.2016.12.010] [PMID: 27956192]
[37]
Prajapati JB, Katariya H, Patel R. Peyer’e patch targeting of isradipine loaded solid lipid nanoparticles: it’s cellular uptake study. J Drug Deliv Sci Technol 2018; 43: 318-26.
[http://dx.doi.org/10.1016/j.jddst.2017.10.017]
[38]
Yasir M, Gaur PK, Puri D, Shehkar P, Kumar SS. Solid lipid nanoparticles approach for lymphatic targeting through intraduodenal delivery of quetiapine fumarate. Curr Drug Deliv 2018; 15: 818-28.
[http://dx.doi.org/10.2174/1567201814666170525121049] [PMID: 28545354]
[39]
Schwarz C, Mehnert W, Lucks JS, Müller RH. Solid lipid nanoparticles (SLN) for controlled drug delivery. I. Production, characterization and sterilization. J Control Release 1994; 30: 83-96.
[http://dx.doi.org/10.1016/0168-3659(94)90047-7]
[40]
Speiser P. Lipidnanopellets als Trägersystem für Arzneimittel zur peroralen Anwendung Google Patents EP0167825B1 1990.
[41]
Battaglia L, Ugazio E. Lipid nano- and microparticles: an overview of patent-related research. J Nanomater 2019; 2019: 22.
[http://dx.doi.org/10.1155/2019/2834941]
[42]
Anand A, Arya M, Kaithwas G, Singh G, Saraf SA. Sucrose stearate as a biosurfactant for development of rivastigmine containing nanostructured lipid carriers and assessment of its activity against dementia in C. elegans model. J Drug Deliv Sci Technol 2019; 49: 219-26.
[http://dx.doi.org/10.1016/j.jddst.2018.11.021]
[43]
Pooja D, Tunki L, Kulhari H, Reddy BB, Sistla R. Optimization of solid lipid nanoparticles prepared by a single emulsification-solvent evaporation method. Data Brief 2016; 6: 15-9.
[http://dx.doi.org/10.1016/j.dib.2015.11.038] [PMID: 26759823]
[44]
Mishra V, Bansal KK, Verma A, et al. Solid lipid nanoparticles: emerging colloidal nano drug delivery systems. Pharmaceutics 2018; 10.
[http://dx.doi.org/10.3390/pharmaceutics10040191] [PMID: 30340327]
[45]
Chen YJ, Jin RX, Zhou YQ, Zeng J, Zhang H, Feng QR. Preparation of solid lipid nanoparticles loaded with Xionggui powder-supercritical carbon dioxide fluid extraction and their evaluation in vitro release. Zhongguo Zhongyao Zazhi 2006; 31: 376-9.
[PMID: 16711418]
[46]
Kaiser CS, Rompp H, Schmidt PC. Pharmaceutical applications of supercritical carbon dioxide. Pharmazie 2001; 56: 907-26.
[PMID: 11802652]
[47]
Gosselin PM, Thibert R, Preda M, McMullen JN. Polymorphic properties of micronized carbamazepine produced by RESS. Int J Pharm 2003; 252: 225-33.
[http://dx.doi.org/10.1016/S0378-5173(02)00649-X] [PMID: 12550798]
[48]
Trucillo P, Campardelli R. Production of solid lipid nanoparticles with a supercritical fluid assisted process. J Supercrit Fluids 2019; 143: 16-23.
[http://dx.doi.org/10.1016/j.supflu.2018.08.001]
[49]
Singh R. Preparation of solid lipid nanoparticles through various methods using different precursors. J Drug Deliv Ther 2019; 9: 415-9.
[http://dx.doi.org/10.22270/jddt.v9i2.2461]
[50]
Stella B, Peira E, Dianzani C, et al. Development and characterization of solid lipid nanoparticles loaded with a highly active doxorubicin derivative. Nanomaterials (Basel) 2018; 8.
[http://dx.doi.org/10.3390/nano8020110] [PMID: 29462932]
[51]
Liu K, Sun J, Wang Y, He Y, Gao K, He Z. Preparation and characterization of 10-hydroxycamptothecin loaded nanostructured lipid carriers. Drug Dev Ind Pharm 2008; 34: 465-71.
[http://dx.doi.org/10.1080/03639040701662230] [PMID: 18473227]
[52]
Jose J, Netto G. Role of solid lipid nanoparticles as photoprotective agents in cosmetics. J Cosmet Dermatol 2019; 18: 315-21.
[http://dx.doi.org/10.1111/jocd.12504] [PMID: 29441672]
[53]
Obeidat WM, Schwabe K, Muller RH, Keck CM. Preservation of nanostructured lipid carriers (NLC). Eur J Pharm Biopharm 2010; 76: 56-67.
[http://dx.doi.org/10.1016/j.ejpb.2010.05.001] [PMID: 20452422]
[54]
Mehnert W, Mäder K. Solid lipid nanoparticles: production, characterization and applications. Adv Drug Deliv Rev 2012; 64: 83-101.
[http://dx.doi.org/10.1016/j.addr.2012.09.021] [PMID: 11311991]
[55]
Tetyczka C, Hodzic A, Kriechbaum M, et al. Comprehensive characterization of nanostructured lipid carriers using laboratory and synchrotron X-ray scattering and diffraction. Eur J Pharm Biopharm 2019; 139: 153-60.
[http://dx.doi.org/10.1016/j.ejpb.2019.03.017] [PMID: 30905779]
[56]
Saupe A, Gordon KC, Rades T. Structural investigations on nanoemulsions, solid lipid nanoparticles and nanostructured lipid carriers by cryo-field emission scanning electron microscopy and Raman spectroscopy. Int J Pharm 2006; 314: 56-62.
[http://dx.doi.org/10.1016/j.ijpharm.2006.01.022] [PMID: 16574354]
[57]
Placzek M, Kosela M. Microscopic methods in analysis of submicron phospholipid dispersions. Acta Pharm 2016; 66: 1-22.
[http://dx.doi.org/10.1515/acph-2016-0003] [PMID: 26959541]
[58]
Das S, Ng WK, Kanaujia P, Kim S, Tan RB. Formulation design, preparation and physicochemical characterizations of solid lipid nanoparticles containing a hydrophobic drug: effects of process variables. Colloids Surf B Biointerfaces 2011; 88: 483-9.
[http://dx.doi.org/10.1016/j.colsurfb.2011.07.036] [PMID: 21831615]
[59]
Oliveira MS, Lima BHS, Goulart GAC, et al. Improved cytotoxic effect of doxorubicin by its combination with sclareol in solid lipid nanoparticle suspension. J Nanosci Nanotechnol 2018; 18: 5609-16.
[http://dx.doi.org/10.1166/jnn.2018.15418] [PMID: 29458616]
[60]
Mendes IT, Ruela ALM, Carvalho FC, Freitas JTJ, Bonfilio R, Pereira GR. Development and characterization of nanostructured lipid carrier-based gels for the transdermal delivery of donepezil. Colloids Surf B Biointerfaces 2019; 177: 274-81.
[http://dx.doi.org/10.1016/j.colsurfb.2019.02.007] [PMID: 30763792]
[61]
Rostamkalaei SS, Akbari J, Saeedi M, Morteza-Semnani K, Nokhodchi A. Topical gel of metformin solid lipid nanoparticles: a hopeful promise as a dermal delivery system. Colloids Surf B Biointerfaces 2019; 175: 150-7.
[http://dx.doi.org/10.1016/j.colsurfb.2018.11.072] [PMID: 30530000]
[62]
Sadati Behbahani E, Ghaedi M, Abbaspour M, Rostamizadeh K, Dashtian K. Curcumin loaded nanostructured lipid carriers: in vitro digestion and release studies. Polyhedron 2019; 164: 113-22.
[http://dx.doi.org/10.1016/j.poly.2019.02.002]
[63]
Rizvi SAA, Saleh AM. Applications of nanoparticle systems in drug delivery technology. Saudi Pharm J 2018; 26: 64-70.
[http://dx.doi.org/10.1016/j.jsps.2017.10.012] [PMID: 29379334]
[64]
Rehman M, Ihsan A, Madni A, et al. Solid lipid nanoparticles for thermoresponsive targeting: evidence from spectrophotometry, electrochemical, and cytotoxicity studies. Int J Nanomedicine 2017; 12: 8325-36.
[http://dx.doi.org/10.2147/IJN.S147506] [PMID: 29200845]
[65]
Chen HH, Huang WC, Chiang WH, et al. pH-Responsive therapeutic solid lipid nanoparticles for reducing P-glycoprotein-mediated drug efflux of multidrug resistant cancer cells. Int J Nanomedicine 2015; 10: 5035-48.
[PMID: 26346762]
[66]
Luo Y, Teng Z, Li Y, Wang Q. Solid lipid nanoparticles for oral drug delivery: chitosan coating improves stability, controlled delivery, mucoadhesion and cellular uptake. Carbohydr Polym 2015; 122: 221-9.
[http://dx.doi.org/10.1016/j.carbpol.2014.12.084] [PMID: 25817662]
[67]
Kong WH, Park K, Lee M-Y, Lee H, Sung DK, Hahn SK. Cationic solid lipid nanoparticles derived from apolipoprotein-free LDLs for target specific systemic treatment of liver fibrosis. Biomaterials 2013; 34: 542-51.
[http://dx.doi.org/10.1016/j.biomaterials.2012.09.067] [PMID: 23092863]
[68]
Taveira SF, De Santana DC, Araujo LM, Marquele-Oliveira F, Nomizo A, Lopez RF. Effect of iontophoresis on topical delivery of doxorubicin-loaded solid lipid nanoparticles. J Biomed Nanotechnol 2014; 10: 1382-90.
[http://dx.doi.org/10.1166/jbn.2014.1834] [PMID: 24804558]
[69]
Serpe L, Catalano MG, Cavalli R, et al. Cytotoxicity of anticancer drugs incorporated in solid lipid nanoparticles on HT-29 colorectal cancer cell line. Eur J Pharm Biopharm 2004; 58: 673-80.
[http://dx.doi.org/10.1016/j.ejpb.2004.03.026] [PMID: 15451544]
[70]
Nafee N, Husari A, Maurer CK, et al. Antibiotic-free nanotherapeutics: ultra-small, mucus-penetrating solid lipid nanoparticles enhance the pulmonary delivery and anti-virulence efficacy of novel quorum sensing inhibitors. J Control Release 2014; 192: 131-40.
[http://dx.doi.org/10.1016/j.jconrel.2014.06.055] [PMID: 24997276]
[71]
Kuo Y-C, Wang C-C. Carmustine-loaded catanionic solid lipid nanoparticles with serotonergic 1B receptor subtype antagonist for in vitro targeted delivery to inhibit brain cancer growth. J Taiwan Inst Chem E 2015; 46: 1-14.
[http://dx.doi.org/10.1016/j.jtice.2014.08.035]
[72]
Zhu X, Huang S, Huang H, et al. In vitro and in vivo anti-cancer effects of targeting and photothermal sensitive solid lipid nanoparticles. J Drug Target 2014; 22: 822-8.
[http://dx.doi.org/10.3109/1061186X.2014.931405] [PMID: 24964053]
[73]
Parveen R, Ahmad FJ, Iqbal Z, Samim M, Ahmad S. Solid lipid nanoparticles of anticancer drug andrographolide: formulation, in vitro and in vivo studies. Drug Dev Ind Pharm 2014; 40: 1206-12.
[http://dx.doi.org/10.3109/03639045.2013.810636] [PMID: 23826860]
[74]
Hashem FM, Nasr M, Khairy A. In vitro cytotoxicity and bioavailability of solid lipid nanoparticles containing tamoxifen citrate. Pharm Dev Technol 2014; 19: 824-32.
[http://dx.doi.org/10.3109/10837450.2013.836218] [PMID: 24032414]
[75]
Zhao B, Gu S, Du Y, Shen M, Liu X, Shen Y. Solid lipid nanoparticles as carriers for oral delivery of hydroxysafflor yellow A. Int J Pharm 2018; 535: 164-71.
[http://dx.doi.org/10.1016/j.ijpharm.2017.10.040] [PMID: 29107614]
[76]
Wang Q, Yang Q, Cao X, et al. Enhanced oral bioavailability and anti-gout activity of [6]-shogaol-loaded solid lipid nanoparticles. Int J Pharm 2018; 550: 24-34.
[http://dx.doi.org/10.1016/j.ijpharm.2018.08.028] [PMID: 30125653]
[77]
Choi MJ, Kim JH, Maibach HI. Topical DNA vaccination with DNA/Lipid based complex. Curr Drug Deliv 2006; 3: 37-45.
[http://dx.doi.org/10.2174/156720106775197484] [PMID: 16472092]
[78]
Das S, Ng WK, Tan RB. Sucrose ester stabilized solid lipid nanoparticles and nanostructured lipid carriers. II. Evaluation of the imidazole antifungal drug-loaded nanoparticle dispersions and their gel formulations. Nanot 2014; 25 105102
[http://dx.doi.org/10.1088/0957-4484/25/10/105102] [PMID: 24531828]
[79]
Mei Z, Wu Q, Hu S, Li X, Yang X. Triptolide loaded solid lipid nanoparticle hydrogel for topical application. Drug Dev Ind Pharm 2005; 31: 161-8.
[http://dx.doi.org/10.1081/DDC-200047791] [PMID: 15773283]
[80]
Jain SK, Chourasia MK, Masuriha R, et al. Solid lipid nanoparticles bearing flurbiprofen for transdermal delivery. Drug Deliv 2005; 12: 207-15.
[http://dx.doi.org/10.1080/10717540590952591] [PMID: 16036715]
[81]
Jenning V, Gysler A, Schafer-Korting M, Gohla SH. Vitamin A loaded solid lipid nanoparticles for topical use: occlusive properties and drug targeting to the upper skin. Eur J Pharm Biopharm 2000; 49: 211-8.
[http://dx.doi.org/10.1016/S0939-6411(99)00075-2] [PMID: 10799811]
[82]
Jenning V, Schafer-Korting M, Gohla S. Vitamin A-loaded solid lipid nanoparticles for topical use: drug release properties. J Control Release 2000; 66: 115-26.
[http://dx.doi.org/10.1016/S0168-3659(99)00223-0] [PMID: 10742573]
[83]
Santos Maia C, Mehnert W, Schaller M, et al. Drug targeting by solid lipid nanoparticles for dermal use. J Drug Target 2002; 10: 489-95.
[http://dx.doi.org/10.1080/1061186021000038364] [PMID: 12575739]
[84]
Liu J, Hu W, Chen H, Ni Q, Xu H, Yang X. Isotretinoin-loaded solid lipid nanoparticles with skin targeting for topical delivery. Int J Pharm 2007; 328: 191-5.
[http://dx.doi.org/10.1016/j.ijpharm.2006.08.007] [PMID: 16978810]
[85]
Souto EB, Muller RH. SLN and NLC for topical delivery of ketoconazole. J Microencapsul 2005; 22: 501-10.
[http://dx.doi.org/10.1080/02652040500162436] [PMID: 16361193]
[86]
Chen H, Chang X, Du D, et al. Podophyllotoxin-loaded solid lipid nanoparticles for epidermal targeting. J Control Release 2006; 110: 296-306.
[http://dx.doi.org/10.1016/j.jconrel.2005.09.052] [PMID: 16325954]
[87]
Fundaro A, Cavalli R, Bargoni A, Vighetto D, Zara GP, Gasco MR. Non-stealth and stealth solid lipid nanoparticles (SLN) carrying doxorubicin: pharmacokinetics and tissue distribution after I.V. administration to rats. Pharmacol Res 2000; 42: 337-43.
[http://dx.doi.org/10.1006/phrs.2000.0695] [PMID: 10987994]
[88]
Zara GP, Cavalli R, Bargoni A, Fundaro A, Vighetto D, Gasco MR. Intravenous administration to rabbits of non-stealth and stealth doxorubicin-loaded solid lipid nanoparticles at increasing concentrations of stealth agent: pharmacokinetics and distribution of doxorubicin in brain and other tissues. J Drug Target 2002; 10: 327-35.
[http://dx.doi.org/10.1080/10611860290031868] [PMID: 12164381]
[89]
Lee MK, Lim SJ, Kim CK. Preparation, characterization and in vitro cytotoxicity of paclitaxel-loaded sterically stabilized solid lipid nanoparticles. Biomaterials 2007; 28: 2137-46.
[http://dx.doi.org/10.1016/j.biomaterials.2007.01.014] [PMID: 17257668]
[90]
Koziara JM, Whisman TR, Tseng MT, Mumper RJ. In-vivo efficacy of novel paclitaxel nanoparticles in paclitaxel-resistant human colorectal tumors. J Control Release 2006; 112: 312-9.
[http://dx.doi.org/10.1016/j.jconrel.2006.03.001] [PMID: 16626835]
[91]
Tabatt K, Kneuer C, Sameti M, et al. Transfection with different colloidal systems: comparison of solid lipid nanoparticles and liposomes. J Control Release 2004; 97: 321-32.
[http://dx.doi.org/10.1016/j.jconrel.2004.02.029] [PMID: 15196759]
[92]
Weber S, Zimmer A, Pardeike J. Solid Lipid Nanoparticles (SLN) and Nanostructured Lipid Carriers (NLC) for pulmonary application: a review of the state of the art. Eur J Pharm Biopharm 2014; 86: 7-22.
[http://dx.doi.org/10.1016/j.ejpb.2013.08.013] [PMID: 24007657]
[93]
Yue-Xing C, Fei-Fei Y, Han W, et al. The effect of l-leucine on the stabilization and inhalability of spray-dried solid lipid nanoparticles for pulmonary drug delivery. J Drug Deliv Sci Technol 2018; 46: 474-81.
[http://dx.doi.org/10.1016/j.jddst.2018.06.011]
[94]
Haque S, Whittaker M, McIntosh MP, Pouton CW, Phipps S, Kaminskas LM. A comparison of the lung clearance kinetics of solid lipid nanoparticles and liposomes by following the 3H-labelled structural lipids after pulmonary delivery in rats. Eur J Pharm Biopharm 2018; 125: 1-12.
[http://dx.doi.org/10.1016/j.ejpb.2018.01.001] [PMID: 29309835]
[95]
Nafee N, Makled S, Boraie N. Nanostructured lipid carriers versus solid lipid nanoparticles for the potential treatment of pulmonary hypertension via nebulization. Eur J Pharm Sci 2018; 125: 151-62.
[http://dx.doi.org/10.1016/j.ejps.2018.10.003] [PMID: 30292750]
[96]
Zhao Y, Chang Y-X, Hu X, Liu C-Y, Quan L-H, Liao Y-H. Solid lipid nanoparticles for sustained pulmonary delivery of Yuxingcao essential oil: preparation, characterization and in vivo evaluation. Int J Pharm 2017; 516: 364-71.
[http://dx.doi.org/10.1016/j.ijpharm.2016.11.046] [PMID: 27884712]
[97]
Makled S, Nafee N, Boraie N. Nebulized solid lipid nanoparticles for the potential treatment of pulmonary hypertension via targeted delivery of phosphodiesterase-5-inhibitor. Int J Pharm 2017; 517: 312-21.
[http://dx.doi.org/10.1016/j.ijpharm.2016.12.026] [PMID: 27979766]
[98]
Paranjpe M, Finke JH, Richter C, et al. Physicochemical characterization of sildenafil-loaded solid lipid nanoparticle dispersions (SLN) for pulmonary application. Int J Pharm 2014; 476: 41-9.
[http://dx.doi.org/10.1016/j.ijpharm.2014.09.031] [PMID: 25261709]
[99]
Varshosaz J, Ghaffari S, Mirshojaei SF, et al. Biodistribution of amikacin solid lipid nanoparticles after pulmonary delivery. BioMed Res Int 2013; 2013136859
[http://dx.doi.org/10.1155/2013/136859] [PMID: 23984315]
[100]
Battaglia L, Serpe L, Foglietta F, et al. Application of lipid nanoparticles to ocular drug delivery. Expert Opin Drug Deliv 2016; 13: 1743-57.
[http://dx.doi.org/10.1080/17425247.2016.1201059] [PMID: 27291069]
[101]
del Pozo-Rodriguez A, Delgado D, Gascon AR, Solinis MA. Lipid nanoparticles as drug/gene delivery systems to the retina. J Ocul Pharmacol Ther 2013; 29: 173-88.
[http://dx.doi.org/10.1089/jop.2012.0128] [PMID: 23286300]
[102]
Sharma AK, Sahoo PK, Majumdar DK, Sharma N, Sharma RK, Kumar A. Fabrication and evaluation of lipid nanoparticulates for ocular delivery of a COX-2 inhibitor. Drug Deliv 2016; 23: 3364-73.
[http://dx.doi.org/10.1080/10717544.2016.1183720] [PMID: 27128623]
[103]
Gokce EH, Sandri G, Bonferoni MC, et al. Cyclosporine A loaded SLNs: evaluation of cellular uptake and corneal cytotoxicity. Int J Pharm 2008; 364: 76-86.
[http://dx.doi.org/10.1016/j.ijpharm.2008.07.028] [PMID: 18725276]
[104]
Gökçe EH, Sandri G, Eğrilmez S, Bonferoni MC, Güneri T, Caramella C. Cyclosporine A-loaded solid lipid nanoparticles: ocular tolerance and in vivo drug release in rabbit eyes. CEyeR 2009; 34: 996-1003.
[http://dx.doi.org/10.3109/02713680903261405] [PMID: 19958116]
[105]
Sandri G, Bonferoni MC, Gökçe EH, et al. Chitosan-associated SLN: in vitro and ex vivo characterization of cyclosporine A loaded ophthalmic systems. J Microencapsul 2010; 27: 735-46.
[http://dx.doi.org/10.3109/02652048.2010.517854] [PMID: 21034366]
[106]
Başaran E, Demirel M, Sırmagül B, Yazan Y. Cyclosporine-A incorporated cationic solid lipid nanoparticles for ocular delivery. J Microencapsul 2010; 27: 37-47.
[http://dx.doi.org/10.3109/02652040902846883] [PMID: 19545226]
[107]
Battaglia L, Panciani PP, Muntoni E, et al. Lipid nanoparticles for intranasal administration: application to nose-to-brain delivery. Expert Opin Drug Deliv 2018; 15: 369-78.
[http://dx.doi.org/10.1080/17425247.2018.1429401] [PMID: 29338427]
[108]
Costa C, Moreira JN, Amaral MH, Sousa Lobo JM, Silva AC. Nose-to-brain delivery of lipid-based nanosystems for epileptic seizures and anxiety crisis. J Control Release 2019; 295: 187-200.
[http://dx.doi.org/10.1016/j.jconrel.2018.12.049] [PMID: 30610952]
[109]
Youssef N, Kassem AA, Farid RM, Ismail FA, El-Massik MAE, Boraie NA. A novel nasal almotriptan loaded solid lipid nanoparticles in mucoadhesive in situ gel formulation for brain targeting: preparation, characterization and in vivo evaluation. Int J Pharm 2018; 548: 609-24.
[http://dx.doi.org/10.1016/j.ijpharm.2018.07.014] [PMID: 30033394]
[110]
Wong HL, Chattopadhyay N, Wu XY, Bendayan R. Nanotechnology applications for improved delivery of antiretroviral drugs to the brain. Adv Drug Deliv Rev 2010; 62: 503-17.
[http://dx.doi.org/10.1016/j.addr.2009.11.020] [PMID: 19914319]
[111]
Edagwa BJ, Zhou T, McMillan JM, Liu XM, Gendelman HE. Development of HIV reservoir targeted long acting nanoformulated antiretroviral therapies. Curr Med Chem 2014; 21: 4186-98.
[http://dx.doi.org/10.2174/0929867321666140826114135] [PMID: 25174930]
[112]
Fontana G, Maniscalco L, Schillaci D, Cavallaro G, Giammona G. Solid lipid nanoparticles containing tamoxifen characterization and in vitro antitumoral activity. Drug Deliv 2005; 12: 385-92.
[http://dx.doi.org/10.1080/10717540590968855] [PMID: 16253954]
[113]
Garg NK, Singh B, Kushwah V, et al. The ligand(s) anchored lipobrid nanoconstruct mediated delivery of methotrexate: an effective approach in breast cancer therapeutics. Nanomedicine 2016; 12: 2043-60.
[http://dx.doi.org/10.1016/j.nano.2016.05.008] [PMID: 27234306]
[114]
Du Y, Ling L, Ismail M, et al. Redox sensitive lipid-camptothecin conjugate encapsulated solid lipid nanoparticles for oral delivery. Int J Pharm 2018; 549: 352-62.
[http://dx.doi.org/10.1016/j.ijpharm.2018.08.010] [PMID: 30099214]
[115]
Lu B, Xiong SB, Yang H, Yin XD, Chao RB. Solid lipid nanoparticles of mitoxantrone for local injection against breast cancer and its lymph node metastases. Eur J Pharm Sci 2006; 28: 86-95.
[http://dx.doi.org/10.1016/j.ejps.2006.01.001] [PMID: 16472996]
[116]
Fundarò A, Cavalli R, Bargoni A, Vighetto D, Zara GP, Gasco MR. Non-stealth and stealth solid lipid nanoparticles (SLN) carrying doxorubicin: pharmacokinetics and tissue distribution after I.V. administration to rats. Pharmacol Res 2000; 42: 337-43.
[http://dx.doi.org/10.1006/phrs.2000.0695] [PMID: 10987994]
[117]
Yue Y, Zhao D, Yin Q. Hyaluronic acid modified nanostructured lipid carriers for transdermal bupivacaine delivery: in vitro and in vivo anesthesia evaluation. Biomed Pharmacother 2018; 98: 813-20.
[http://dx.doi.org/10.1016/j.biopha.2017.12.103] [PMID: 29571251]
[118]
Han Y, Zhang Y, Li D, Chen Y, Sun J, Kong F. Transferrin-modified nanostructured lipid carriers as multifunctional nanomedicine for codelivery of DNA and doxorubicin. Int J Nanomedicine 2014; 9: 4107-16.
[PMID: 25187713]
[119]
Kuo Y-C, Wang L-J. Transferrin-grafted catanionic solid lipid nanoparticles for targeting delivery of saquinavir to the brain. J Taiwan Inst Chem E 2014; 45: 755-63.
[http://dx.doi.org/10.1016/j.jtice.2013.09.024]
[120]
Hamishehkar H, Bahadori MB, Vandghanooni S, Eskandani M, Nakhlband A, Eskandani M. Preparation, characterization and anti-proliferative effects of sclareol-loaded solid lipid nanoparticles on A549 human lung epithelial cancer cells. J Drug Deliv Sci Technol 2018; 45: 272-80.
[http://dx.doi.org/10.1016/j.jddst.2018.02.017]
[121]
Guney Eskiler G, Cecener G, Dikmen G, Egeli U, Tunca B. Solid lipid nanoparticles: reversal of tamoxifen resistance in breast cancer. Eur J Pharm Sci 2018; 120: 73-88.
[http://dx.doi.org/10.1016/j.ejps.2018.04.040] [PMID: 29719240]
[122]
Wang F, Li L, Liu B, Chen Z, Li C. Hyaluronic acid decorated pluronic P85 solid lipid nanoparticles as a potential carrier to overcome multidrug resistance in cervical and breast cancer. Biomed Pharmacother 2017; 86: 595-604.
[http://dx.doi.org/10.1016/j.biopha.2016.12.041] [PMID: 28027535]
[123]
Rompicharla SVK, Bhatt H, Shah A, et al. Formulation optimization, characterization, and evaluation of in vitro cytotoxic potential of curcumin loaded solid lipid nanoparticles for improved anticancer activity. CPLip 2017; 208: 10-8.
[http://dx.doi.org/10.1016/j.chemphyslip.2017.08.009] [PMID: 28842128]
[124]
Soni N, Soni N, Pandey H, Maheshwari R, Kesharwani P, Tekade RK. Augmented delivery of gemcitabine in lung cancer cells exploring mannose anchored solid lipid nanoparticles. J Colloid Interface Sci 2016; 481: 107-16.
[http://dx.doi.org/10.1016/j.jcis.2016.07.020] [PMID: 27459173]
[125]
Pandey R, Sharma S, Khuller GK. Oral solid lipid nanoparticle-based antitubercular chemotherapy. Tuberculosis (Edinb) 2005; 85: 415-20.
[http://dx.doi.org/10.1016/j.tube.2005.08.009] [PMID: 16256437]
[126]
Pandey R, Khuller GK. Solid lipid particle-based inhalable sustained drug delivery system against experimental tuberculosis. Tuberculosis (Edinb) 2005; 85: 227-34.
[http://dx.doi.org/10.1016/j.tube.2004.11.003] [PMID: 15922668]
[127]
Santos-Magalhães NS, Mosqueira VCF. Nanotechnology applied to the treatment of malaria. Adv Drug Deliv Rev 2010; 62: 560-75.
[http://dx.doi.org/10.1016/j.addr.2009.11.024] [PMID: 19914313]
[128]
Omwoyo WN, Melariri P, Gathirwa JW, et al. Development, characterization and antimalarial efficacy of dihydroartemisinin loaded solid lipid nanoparticles. Nanomed Nanotechnol Biol Med 2016; 12: 801-9.
[http://dx.doi.org/10.1016/j.nano.2015.11.017] [PMID: 26724538]
[129]
Ahangarpour A, Oroojan AA, Khorsandi L, Kouchak M, Badavi M. Solid lipid nanoparticles of myricitrin have antioxidant and antidiabetic effects on streptozotocin-nicotinamide-induced diabetic model and myotube cell of male mouse. Oxid Med Cell Longev 2018; 2018: 18.
[http://dx.doi.org/10.1155/2018/7496936] [PMID: 30116491]
[130]
Ansari MJ, Anwer MK, Jamil S, et al. Enhanced oral bioavailability of insulin-loaded solid lipid nanoparticles: pharmacokinetic bioavailability of insulin-loaded solid lipid nanoparticles in diabetic rats. Drug Deliv 2016; 23: 1972-9.
[PMID: 26017100]
[131]
Sarker S, Ali MA, Barman RK, et al. Preparation and antidiabetic effect of orally administered nifedipine-loaded solid lipid nanoparticles in fructose-induced diabetic rats. Pharmacol Pharm 2018; 09: 457-71.
[132]
Ganesan P, Ramalingam P, Karthivashan G, Ko YT, Choi D-K. Recent developments in solid lipid nanoparticle and surface-modified solid lipid nanoparticle delivery systems for oral delivery of phyto-bioactive compounds in various chronic diseases. Int J Nanomedicine 2018; 13: 1569-83.
[http://dx.doi.org/10.2147/IJN.S155593] [PMID: 29588585]
[133]
Dhawan S, Kapil R, Singh B. Formulation development and systematic optimization of solid lipid nanoparticles of quercetin for improved brain delivery. J Pharm Pharmacol 2011; 63: 342-51.
[http://dx.doi.org/10.1111/j.2042-7158.2010.01225.x] [PMID: 21749381]
[134]
Ramalingam P, Ko YT. Enhanced oral delivery of curcumin from N-trimethyl chitosan surface-modified solid lipid nanoparticles: pharmacokinetic and brain distribution evaluations. Pharm Res 2015; 32: 389-402.
[http://dx.doi.org/10.1007/s11095-014-1469-1] [PMID: 25082210]
[135]
Ramalingam P, Ko YT. Improved oral delivery of resveratrol from N-trimethyl chitosan-g-palmitic acid surface-modified solid lipid nanoparticles. Colloids Surf B Biointerfaces 2016; 139: 52-61.
[http://dx.doi.org/10.1016/j.colsurfb.2015.11.050] [PMID: 26700233]
[136]
Kakkar V, Kaur IP. Evaluating potential of curcumin loaded solid lipid nanoparticles in aluminium induced behavioural, biochemical and histopathological alterations in mice brain. Food Chem Toxicol 2011; 49: 2906-13.
[http://dx.doi.org/10.1016/j.fct.2011.08.006] [PMID: 21889563]
[137]
Loureiro JA, Andrade S, Duarte A, et al. Resveratrol and grape extract-loaded solid lipid nanoparticles for the treatment of Alzheimer’s disease. Molecules 2017; 22.
[http://dx.doi.org/10.3390/molecules22020277] [PMID: 28208831]
[138]
Prow T, Smith JN, Grebe R, et al. Construction, gene delivery, and expression of DNA tethered nanoparticles. Mol Vis 2006; 12: 606-15.
[PMID: 16760897]
[139]
Husseini GA, Pitt WG. Micelles and nanoparticles for ultrasonic drug and gene delivery. Adv Drug Deliv Rev 2008; 60: 1137-52.
[http://dx.doi.org/10.1016/j.addr.2008.03.008] [PMID: 18486269]
[140]
del Pozo-Rodríguez A, Delgado D, Solinís MA, Gascón AR, Pedraz JL. Solid lipid nanoparticles for retinal gene therapy: transfection and intracellular trafficking in RPE cells. Int J Pharm 2008; 360: 177-83.
[http://dx.doi.org/10.1016/j.addr.2008.03.008] [PMID: 18486269]
[141]
Apaolaza PS, del Pozo-Rodríguez A, Solinís MA, et al. Structural recovery of the retina in a retinoschisin-deficient mouse after gene replacement therapy by solid lipid nanoparticles. Biomaterials 2016; 90: 40-9.
[http://dx.doi.org/10.1016/j.biomaterials.2016.03.004] [PMID: 26986855]
[142]
Vicente-Pascual M, Albano A, Solinis MA, et al. Gene delivery in the cornea: in vitro & ex vivo evaluation of solid lipid nanoparticle-based vectors. Nanomedicine (Lond) 2018; 13: 1847-54.
[http://dx.doi.org/10.2217/nnm-2018-0112] [PMID: 29792369]
[143]
Zhang WL, Liu JP, Liu XX, Chen ZQ. Stealth tanshinone IIA-loaded solid lipid nanoparticles: effects of poloxamer 188 coating on in vitro phagocytosis and in vivo pharmacokinetics in rats. Yao Xue Xue Bao 2009; 44: 1421-8.
[PMID: 21348419]
[144]
Zhang W, Liu J, Li S, Chen M, Liu H. Preparation and evaluation of stealth Tashinone IIA-loaded solid lipid nanoparticles: influence of Poloxamer 188 coating on phagocytic uptake. J Microencapsul 2008; 25: 203-9.
[http://dx.doi.org/10.1080/02652040701852181] [PMID: 18382927]
[145]
Lanza GM, Wickline SA. Targeted ultrasonic contrast agents for molecular imaging and therapy. Prog Cardiovasc Dis 2001; 44: 13-31.
[http://dx.doi.org/10.1053/pcad.2001.26440] [PMID: 11533924]
[146]
Saljoughian N, Taheri T, Zahedifard F, et al. Development of novel prime-boost strategies based on a tri-gene fusion recombinant L. tarentolae vaccine against experimental murine visceral leishmaniasis. PLoS Negl Trop Dis 2013; 7e2174
[http://dx.doi.org/10.1371/journal.pntd.0002174] [PMID: 23638195]
[147]
Doroud D, Rafati S. Leishmaniasis: focus on the design of nanoparticulate vaccine delivery systems. Expert Rev Vaccines 2012; 11: 69-86.
[http://dx.doi.org/10.1586/erv.11.166] [PMID: 22149710]
[148]
Doroud D, Zahedifard F, Vatanara A, et al. Delivery of a cocktail DNA vaccine encoding cysteine proteinases type I, II and III with solid lipid nanoparticles potentiate protective immunity against Leishmania major infection. J Control Release 2011; 153: 154-62.
[http://dx.doi.org/10.1016/j.jconrel.2011.04.011] [PMID: 21530597]
[149]
Doroud D, Vatanara A, Zahedifard F, et al. Cationic solid lipid nanoparticles loaded by cysteine proteinase genes as a novel anti-leishmaniasis DNA vaccine delivery system: characterization and in vitro evaluations. J Pharm Pharm Sci 2010; 13: 320-35.
[http://dx.doi.org/10.18433/J3R30T] [PMID: 21092706]
[150]
Lai F, Wissing SA, Muller RH, Fadda AM. Artemisia arborescens L. essential oil-loaded solid lipid nanoparticles for potential agricultural application: preparation and characterization. AAPS PharmSciTech 2006; 7E2
[http://dx.doi.org/10.1208/pt070102] [PMID: 16584150]
[151]
Nesseem D. Formulation of sunscreens with enhancement sun protection factor response based on solid lipid nanoparticles. Int J Cosmet Sci 2011; 33: 70-9.
[http://dx.doi.org/10.1111/j.1468-2494.2010.00598.x] [PMID: 20704600]
[152]
Marcato PD, Caverzan J, Rossi-Bergmann B, et al. Nanostructured polymer and lipid carriers for sunscreen. Biological effects and skin permeation. J Nanosci Nanotechnol 2011; 11: 1880-6.
[http://dx.doi.org/10.1166/jnn.2011.3135] [PMID: 21449324]
[153]
Sanad RA, Abdel Malak NS, El-Bayoomy TS, Badawi AA. Preparation and characterization of oxybenzone-loaded solid lipid nanoparticles (SLNs) with enhanced safety and sunscreening efficacy: SPF and UVA-PF. Drug Discov Ther 2010; 4: 472-83.
[PMID: 22491313]
[154]
Montenegro L. Lipid-Based nanoparticles as carriers for dermal delivery of antioxidants. Curr Drug Metab 2017; 18: 469-80.
[http://dx.doi.org/10.2174/1389200218666170222152038] [PMID: 28228079]
[155]
Beloqui A, Solinís MÁ, Rodríguez-Gascón A, Almeida AJ, Préat V. Nanostructured lipid carriers: promising drug delivery systems for future clinics. Nanomed Nanotechnol Biol Med 2016; 12: 143-61.
[http://dx.doi.org/10.1016/j.nano.2015.09.004] [PMID: 26410277]
[156]
Nanjwade BK. Functions of lipids for enhancement of oral bioavailability of poorly water-soluble drugs. Sci Pharm 2011; 79: 705-27.
[http://dx.doi.org/10.3797/scipharm.1105-09] [PMID: 22145101]
[157]
Kalepu S, Manthina M, Padavala V. Oral lipid-based drug delivery systems - an overview. Acta Pharm Sin B 2013; 3: 361-72.
[http://dx.doi.org/10.1016/j.apsb.2013.10.001]
[158]
Uner M, Yener G. Importance of solid lipid nanoparticles (SLN) in various administration routes and future perspectives. Int J Nanomedicine 2007; 2: 289-300.
[PMID: 18019829]
[159]
Severino P, Andreani T, Macedo AS, et al. Current state-of-art and new trends on lipid nanoparticles (SLN and NLC) for oral drug delivery. J Drug Deliv 2012; 2012: 1-10.
[http://dx.doi.org/10.1155/2012/750891] [PMID: 22175030]


Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 25
ISSUE: 37
Year: 2019
Page: [3943 - 3959]
Pages: 17
DOI: 10.2174/1381612825666190903155321
Price: $65

Article Metrics

PDF: 22
HTML: 7